CiMaas recently applied for a classification for its’ Advanced Therapeutic Medicinal Product, adoptive NK cell therapy for multiple myeloma. Upon this request, the European Medicines Agency / Committee for Advanced Therapies considers that product NK-Xpand-MM1 falls within the definition of somatic cell therapy medicinal product, as provided in Article 2 of Regulation (EC) No 1394/2007. This… Read more »
Mercurius Heerlen B.V. and Werker Beleggingsmaatschappij B.V. invested a second round in CiMaas B.V. to realize cancer immunotherapy.This brings CiMaas again a step closer to fund its’ development of cellular therapies into clinical trials for the patients with multiple myeloma and lung cancer.
Mr Alexander Vos joined the Supervisory Board of CiMaas in May 2018. Alexander Vos is the former CEO of PharmaCell BV, based in Maastricht and Geleen.
CiMaas announced the granting of a European Patent on its Dendritic Cells maturation technology, an essential part of its Dendritic Cell Vaccine Product.
CiMaas moves it’s clinical production site to InSciTe in Sittard-Geleen. Working together in the Biomedical Accelerator Matrix, CiMaas and InSciTe are joining forces to bring a cure for cancer one step closer to reality.
MAASTRICHT, Mercurius Beleggingsmaatschappij B.V. and Werker Beleggingsmaatschappij B.V. invest in CiMaas B.V. to realize cancer immunotherapy. CiMaas is now able to start a clinical trial in late 2017 for lung cancer patients with a cellular vaccine that will stimulate the patients’ own immune system to fight the disease.
The province of Limburg, through LBDF, has awarded CiMaas a subsidy for further development of the new technology for large scale production of NK cell immunotherapy. Under the subsidy, CiMaas collaborates with the department of Haematology of the MUMC+ and an American biotech company to further optimize the treatment.
CiMaas has signed an agreement with London-based Cancer Research Technology, the commercial arm of the charity Cancer Research UK, and the University of Copenhagen under which CiMaas will test a proprietary monoclonal antibody in combination with natural killer cells for the treatment of cancer.
Post
CiMaas appoints Professor Dr J. Aerts and Professor Dr J. Haanen to the Scientific Advisory Board
As of 18 february 2016 CiMaas has appointed the renowned oncologists Professor Dr Joachim Aerts and Professor Dr John Haanen as member of the Scientific Advisory Board of CiMaas.
CiMaas focuses on the development of cellular immunotherapy for the treatment of cancer. One of these therapies is based on healthy donor derived Natural Killer cells to treat cancer patients.